What is NeuroPace?
Founded in 1997 and headquartered in Mountain View, California, NeuroPace specializes in the design, development, and manufacturing of sophisticated implantable devices. The company is best known for its responsive stimulation systems, which are engineered to treat neurological disorders by monitoring brain activity and delivering targeted electrical pulses. This precision-based approach to neuromodulation represents a critical advancement in the medical device sector, offering a personalized therapeutic pathway for patients who have historically faced limited treatment options. Through rigorous research and development, NeuroPace has established a robust intellectual property portfolio that supports its mission to improve quality of life through innovative bioelectronic medicine.
How much funding has NeuroPace raised?
NeuroPace has raised a total of $323.2M across 7 funding rounds:
Private Equity
$49.1M
Private Equity
$18.1M
Series A
$72M
Private Equity
$74M
Debt
$2M
Other Financing Round
$33M
Debt
$75M
Private Equity (2011): $49.1M, investors not publicly disclosed
Private Equity (2013): $18.1M, investors not publicly disclosed
Series A (2016): $72M, investors not publicly disclosed
Private Equity (2017): $74M featuring OrbiMed
Debt (2020): $2M backed by PPP
Other Financing Round (2020): $33M with participation from Accelmed Partners, Revelation Partners, Soleus Capital, OrbiMed, and KCK Group
Debt (2025): $75M led by MidCap Financial
Key Investors in NeuroPace
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms to support innovation at various development stages.
Revelation Partners
Revelation Partners provides flexible capital solutions for rapidly growing healthcare companies, focusing on shareholder liquidity and growth capital to accelerate development within the healthcare ecosystem.
MidCap Financial
MidCap Financial Investment Corporation is a specialized investment firm based in New York that provides strategic financial solutions to support corporate growth and operational requirements.
What's next for NeuroPace?
With the recent influx of capital, NeuroPace is well-positioned to accelerate its commercial expansion and deepen its investment in next-generation neurostimulation platforms. The company's strategic roadmap likely involves scaling its manufacturing capabilities to meet rising demand while simultaneously pursuing clinical trials to expand the indications for its core technology. By maintaining a focus on operational excellence and clinical efficacy, NeuroPace is poised to navigate the evolving healthcare landscape, leveraging its strong investor base to drive long-term value creation and sustained growth in the competitive life sciences market.
See full NeuroPace company page
